- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 27.11. | ZVSA stock touches 52-week low at $1.03 amid sharp annual decline | 1 | Investing.com | ||
| 27.11. | ZVSA-Aktie erreicht 52-Wochen-Tief bei 1,03 US-Dollar | 2 | Investing.com Deutsch | ||
| 20.11. | ZyVersa reports progress on stroke-related heart injury treatment | 1 | Investing.com | ||
| 20.11. | ZyVersa meldet Fortschritte bei der Behandlung von schlaganfallbedingten Herzschäden | 3 | Investing.com Deutsch | ||
| 20.11. | ZyVersa Therapeutics Announces Peer-Reviewed Publication Demonstrating That Inflammasome ASC Inhibitor IC 100 Protects Against Stroke-Related Cardiovascular Injury and Dysfunction in Preclinical Trial | 1 | GlobeNewswire (USA) | ||
| 14.11. | ZyVersa Therapeutics GAAP EPS of -$2.43 misses by $0.83 | 1 | Seeking Alpha | ||
| ZYVERSA THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 14.11. | ZyVersa Therapeutics Reports Third Quarter, 2024 Financial Results and Provides Business Update | 73 | GlobeNewswire (Europe) | KEY BUSINESS HIGHLIGHTS Phase 2a clinical trial for Cholesterol Efflux Mediator VAR 200 in patients with diabetic kidney disease expected to begin Q1-2025.New Obesity, Metabolic & Inflammatory Disease... ► Artikel lesen | |
| 14.11. | ZyVersa Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 14.11. | ZyVersa Therapeutics, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 08.11. | ZVSA stock plunges to 52-week low, hitting $1.34 amid market challenges | 1 | Investing.com | ||
| 05.11. | ZyVersa reports progress on obesity inflammation treatment | 4 | Investing.com | ||
| 05.11. | ZyVersa Therapeutics Highlights Published Data Demonstrating the Potential of Inflammasome Inhibition to Protect Pancreatic Islet Beta Cells and Attenuate Progression from Obesity to Insulin Resistance and Type 2 Diabetes | 1 | GlobeNewswire (USA) | ||
| 30.10. | ZyVersa Therapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 29.10. | ZyVersa Therapeutics Highlights Review Article Supporting the Need for Drug Therapies to Treat the Inflammation of Obesity in Addition to Weight Loss Drugs | 1 | GlobeNewswire (USA) | ||
| 22.10. | ZyVersa Therapeutics Highlights Published Data Demonstrating That Obesity Results in Neuroinflammation Implicated in Development of Neurodegenerative Diseases | 1 | GlobeNewswire (USA) | ||
| 17.10. | ZyVersa macht Fortschritte bei Medikament gegen Fettleibigkeit mit wichtigen Meilensteinen in Aussicht | 5 | Investing.com Deutsch | ||
| 17.10. | ZyVersa advances obesity drug with key milestones ahead | 5 | Investing.com | ||
| 17.10. | ZyVersa Therapeutics CEO, Stephen C. Glover, Issues Letter to Shareholders Highlighting Obesity Development Plans for Inflammasome ASC Inhibitor IC 100 Over the Next Nine Months | 76 | GlobeNewswire (Europe) | Lead indication for ZyVersa's Inflammasome ASC Inhibitor IC 100 is obesity with metabolic complications. WESTON, Fla., Oct. 17, 2024 (GLOBE NEWSWIRE) -- ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA,... ► Artikel lesen | |
| 15.10. | ZyVersa Therapeutics CEO, Stephen C. Glover, Was a Featured Guest on The Big Biz Show to Discuss Current Trends in the Obesity Drug Market and the Potential Role of Inflammasome Inhibitors | 1 | GlobeNewswire (USA) | ||
| 07.10. | ZyVersa Therapeutics Forms New Scientific Advisory Board to Support Development of Inflammasome ASC Inhibitor IC 100 for Obesity with Metabolic Complications | 3 | GlobeNewswire (USA) |
Seite:
1 2 3 Weiter >>
44 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| NEUROCRINE BIOSCIENCES | 139,03 | 0,00 % | Neurocrine Announces Commercial Launch Of Crenessity In US | WASHINGTON (dpa-AFX) - Neurocrine Biosciences, Inc. (NBIX), Friday announced the commercial launch of Crenessity in the U.S. for adult and pediatric patients with classic congenital adrenal... ► Artikel lesen | |
| AMGEN | 263,24 | -0,47 % | Spotlight on Amgen: Analyzing the Surge in Options Activity | ||
| BIOGEN | 149,90 | 0,00 % | BMO cuts rating on Merck and Biogen, on lack of near term catalyst | ||
| IDEXX LABORATORIES | 417,11 | 0,00 % | Jim Cramer on IDEXX Laboratories (IDXX): Is This Pet Stock Poised for a Comeback? | ||
| REGENERON PHARMACEUTICALS | 716,74 | +0,32 % | Regeneron Pharma: Phase 3 Trial With EYLEA HD 8 Mg Meets Primary Endpoint | BRUSSELS/FRANKFURT/PARIS (dpa-AFX) - Regeneron Pharmaceuticals (REGN) announced the primary endpoint was met in the Phase 3 QUASAR trial investigating EYLEA HD or aflibercept injection 8 mg... ► Artikel lesen | |
| SAREPTA THERAPEUTICS | 123,37 | +1,21 % | Sarepta awarded $115.2M in Vyondys 53 patent case: report | ||
| MODERNA | 40,440 | 0,00 % | Moderna-Deutschland-Chef im Interview (2): "Onkologie ist ein bedeutendes Forschungsfeld für ... | Die Aktie von Moderna hat sich in den vergangenen Monaten alles andere als erfreulich entwickelt. Im Mai notierte das Papier noch über 170 Dollar. Mittlerweile steht seitdem ein Kursverlust von 77 Prozent... ► Artikel lesen | |
| QUANTUM-SI | 2,150 | 0,00 % | Quantum-Si präsentiert ProteoVue-Software für Proteinforschung | ||
| VAXCYTE | 85,78 | 0,00 % | Vaxcyte a new buy at Goldman Sachs on vaccine platform, pneumonia asset | ||
| GERON | 3,300 | 0,00 % | Geron Gets Positive CHMP Opinion For RYTELO In Transfusion-Dependent Anemia Due To Lower-Risk MDS | WASHINGTON (dpa-AFX) - Geron Corporation (GERN), a commercial-stage biopharmaceutical company, Friday said that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 7,660 | 0,00 % | Recursion Pharmaceuticals Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing Rules | Salt Lake City, Utah, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Recursion Pharmaceuticals, Inc. ("Recursion") (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug... ► Artikel lesen | |
| HALOZYME THERAPEUTICS | 48,030 | +1,03 % | Evotec: COO-Abgang und Halozyme-Übernahmepläne | Dr. Craig Johnstone, COO von Evotec, verlässt das Unternehmen nach zwölf Jahren, während ein internes Team vorübergehend seine Aufgaben übernimmt. Parallel brodelt die Gerüchteküche um eine mögliche... ► Artikel lesen | |
| TEMPUS AI | 35,230 | 0,00 % | Tempus AI (NASDAQ:TEM) Shares Down 5.7% Following Insider Selling | ||
| GUARDANT HEALTH | 31,370 | 0,00 % | Guardant Health Reports Third Quarter 2024 Financial Results and Increases 2024 Revenue Guidance | PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today reported financial results for the quarter ended September 30, 2024.
Third Quarter... ► Artikel lesen | |
| IOVANCE BIOTHERAPEUTICS | 7,600 | 0,00 % | Iovance Biotherapeutics, Inc.: Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) | SAN CARLOS, Calif., Dec. 20, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the "Company"), a biotechnology company focused on innovating, developing, and delivering... ► Artikel lesen |
Das Unternehmen ZYVERSA THERAPEUTICS INC kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 1,210 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ZYVERSA THERAPEUTICS INC finden Sie auf Wallstreet Online.
